Changing Lifestyles Necessitate Change in Game Plan of Breast Cancer Therapeutics Providers
The changing lifestyles and the growing issue of obesity have heightened the risk of breast cancer amongst women in recent years. Statistics indicate that breast cancer has become the second largest cause of fatalities across the globe. Thus, the increasing number initiatives to raise awareness about this deadly disease and treat patients for this disease has boosted the global breast cancer therapeutics market. The increasing awareness amongst patients about the disease and improving accessibility to premium treatments has also augmented the sales of various drugs in this market. Effective research and development for new treatments to efficiently treat breast cancer is also expected to change the game for this market.
Transparency Market Research forecasts that the global breast cancer therapeutics market is expected to be worth US$16.21 bn by 2023 as compared to US$7.17 bn in 2014, surging at a CAGR of 8.4% between 2015 and 2023. The drastically changing reproductive patterns are also responsible for soaring revenue earnings of the breast cancer therapeutics market. The delayed childbearing age, reduced breastfeeding periods, intake of oral contraceptives, and resorting to hormonal therapies to solve other medical conditions is also contributing towards the growth of this market.
Higher Percentage of Survivors in North America Puts Region in the Lead
A study conducted by World Cancer Research Fund International (WCRF) stated that North America has the highest percentage of breast cancer survivors after diagnoses, while it is the lowest in the developing countries of Asia and Africa. However, breast cancer continues to be a serious health concern in South America, Africa, and Asia.
WRCF also states that North America has a high incidence of breast cancer, however, the breast cancer therapeutics market is progressing in this region due to supportive insurance schemes meted by the government. The overall North America breast cancer therapeutics market is expected to surge at 7.3% CAGR between 2015 and 2023 during the forecast period. The risks of post-treatment complications and relapse are the only two key factors hampering this regional market.
Accurate Diagnosis through HER2 Inhibitors Increases Preference for the Drug Class
Amongst the various drug classes, the HER2 inhibitors segment was the leading segment in 2014. During the forecast period, the HER2 inhibitors segment is expected to expand at a CAGR of 6.2% due to their ability to deliver accurate diagnostics. HER2 inhibitors are used in case of metastatic breast cancer (MBC) patients who have undergone a minimum of two chemotherapeutic schedules of taxane and anthracycline. All of these factors are expected to raise the market opportunity of the HER2 inhibitors segment to a significant amount by the end of forecast period.
The key players operating in the global breast cancer therapeutics market are GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Puma Biotechnology, Novartis International AG, and Sanofi S.A. Companies are focusing on research and development to launch new products along with acquiring small companies to improve the existing line of products. However, these companies are governed by strict regulatory framework, which often causes delay in launching products.
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
2 Executive Summary
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
3 Global Breast Cancer Therapeutics Market - Market Overview
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
184.108.40.206 Higher Incidence Rate
220.127.116.11 Demographic Transition
18.104.22.168 Rising Prevalence Of Obesity
22.214.171.124 Diagnostic Screening Programs
126.96.36.199 Increase in Private Health Insurance Plans:
188.8.131.52 Generic Drugs: Substitute Branded Drugs
184.108.40.206 Intense Competition: Fall in Prices
220.127.116.11 Access barriers due to high drug costs
18.104.22.168 Absence of Social Health Insurance
22.214.171.124 Serious Side Effects of Breast Cancer Therapeutics
126.96.36.199 Countries Lacking Women Empowerment
188.8.131.52 Newer medication options
184.108.40.206 Potential Growth of Domestic Pharmaceutical Companies
220.127.116.11 Combination Drug Therapy
18.104.22.168 Technological Advancements and Robust Trends of Drug Approval
22.214.171.124 New Companion Diagnostics Models
126.96.36.199 Drug Therapy for Triple Negative (TNBC)
188.8.131.52 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
4 Market Segmentation – By Drug Class
4.2 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
5 Market Segmentation – By Geography
5.2 Global Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
184.108.40.206 Rest of Latin America
5.6.2 Middle East and Africa
7 Company Profiles
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
7.10 Teva Pharmaceutical Industries Ltd.
This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report include pharmaceutical companies and intermediaries engaged in the new drug discovery, pipeline development of various breast cancer therapeutics as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global breast cancer therapeutics market with respect to the leading market segments in terms of geography.
The global breast cancer therapeutics market has been studied based on major drug class segments, and their regional as well as national markets. Based on drug class, the global market has been categorized into five major segments: HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptors. The market for these segments and sub-segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments, considering 2014 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the breast cancer therapeutics market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is illustrated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.
Geographically, the breast cancer therapeutics market has been segmented into five regions: North America (the U.S. and Canada), Europe (the U.K., Germany, and Rest of Europe), Asia Pacific (Japan, South Korea, and Rest of APAC), Latin America (Brazil and Rest of Latin America), and Middle East & Africa (MEA). Market revenue in terms of US$ Mn and CAGR % from 2015 to 2023 are provided for all the regions and countries, considering 2014 as the base year.
The recommendations section included in the report would assist existing market players in expanding their market shares and new pharmaceutical companies in establishing their presence in the global breast cancer market. The report also profiles leading and emerging new players in the breast cancer therapeutics market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
The global breast cancer therapeutics market has been segmented as follows:
Global Breast Cancer Therapeutics Market, by Drug Class
- Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
- Herceptin (Trastuzumab)
- Tykerb (Lapatinib)
- Perjeta (Pertuzumab)
- Kadcyla (Ado-trastuzumab emtansine)
- Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
- Halaven (Eribulin)
- Taxotere (Docetaxel)
- Ixempra (Ixabepilone)
- Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
- Gemzar (Gemcitabine)
- Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
- Femara (Leterozole)
- Aromasin (Exemestane)
- Arimidex (Anastrozole)
- Ibrance (Palbociclib)
- Afinitor (Everolimus)
- Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
Global Breast Cancer Therapeutics Market, by Geography
- North America
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa (MEA)